PDE6G — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1327741	0.79	6/20
SCHEMBL1327318	0.81	5/20
SCHEMBL1327321	0.81	5/20
SCHEMBL1327324	0.81	5/20
SCHEMBL972494	0.72	5/20
SCHEMBL972096	0.60	5/20
SCHEMBL2792231	0.54	5/20
SCHEMBL969605	0.77	4/20
SCHEMBL2791914	0.63	4/20
SCHEMBL2485688	0.58	4/20
SCHEMBL969760	0.51	4/20
SCHEMBL1696249	0.51	4/20
SCHEMBL2576880	1.00	3/20
SCHEMBL2568447	0.74	3/20
SCHEMBL968670	0.73	3/20
SCHEMBL972290	0.73	3/20
SCHEMBL971800	0.72	3/20
SCHEMBL867299	0.72	3/20
SCHEMBL1326458	0.72	3/20
SCHEMBL1922041	0.72	3/20

Clinical trials — most relevant to PDE6G by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study	PHASE4	COMPLETED
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis	PHASE4	COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer	PHASE3	RECRUITING
Oral N-acetylcysteine for Retinitis Pigmentosa	PHASE3	ACTIVE_NOT_RECRUITING
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
PDE6A Gene Therapy for Retinitis Pigmentosa	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Promising ROd-cone DYstrophy Gene therapY	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease	PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder	PHASE2	UNKNOWN
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients	PHASE1/PHASE2	COMPLETED
Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED	PHASE2	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye	PHASE1	COMPLETED
Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults	PHASE1	COMPLETED
A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women	PHASE1	COMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial	nan	COMPLETED
Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa	nan	ACTIVE_NOT_RECRUITING
Prospective Natural History Study of Retinitis Pigmentosa	nan	ACTIVE_NOT_RECRUITING
Retrospective Natural History Study of Retinitis Pigmentosa	nan	UNKNOWN
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN
Shock Wave vs. On-demand Tadalafil for Erectile Dysfunction	nan	UNKNOWN
Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery	nan	NOT_YET_RECRUITING
Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE6G binder may also engage these)

Protein	Name	Similarity
P61248	—	1.000	P61248 →
P04972	—	1.000	P04972 →
Q9EQQ8	—	1.000	Q9EQQ8 →
P54827	—	1.000	P54827 →
P61250	—	0.996	P61250 →
P28974	—	0.994	P28974 →
P22571	—	0.994	P22571 →
Q2N9B5	—	0.994	Q2N9B5 →
B7IA35	—	0.993	B7IA35 →
P09174	—	0.993	P09174 →
Q8TAG6	—	0.993	Q8TAG6 →
O29734	—	0.993	O29734 →
P03045	—	0.993	P03045 →
Q66KZ1	—	0.993	Q66KZ1 →
A1DL98	—	0.992	A1DL98 →
PDE6H	Retinal cone rhodopsin-sensitive cGMP 3',5'-c	0.992	landscape →
Q9QSQ6	—	0.992	Q9QSQ6 →
Q04558	—	0.992	Q04558 →
Q5RDL5	—	0.992	Q5RDL5 →
B5FG13	—	0.992	B5FG13 →
O70903	—	0.992	O70903 →
A3N3B7	—	0.992	A3N3B7 →
Q1X711	—	0.992	Q1X711 →
P12731	—	0.992	P12731 →
Q5R5R7	—	0.992	Q5R5R7 →
P75576	—	0.992	P75576 →
A5WCJ4	—	0.992	A5WCJ4 →
P24741	—	0.992	P24741 →
O59835	—	0.992	O59835 →
C3KVP7	—	0.992	C3KVP7 →